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LETTERS TO THE EDITOR
Regarding “Stroke after varicose vein foam injection
sclerotherapy”
We and many others have read with considerable interest the
well-documented report from the St. James Hospital, Dublin
group Forlee et al (J Vasc Surg 2006;43:162-4) regarding the
patient with hemiparesis after duplex-guided foam sclerotherapy.
There appeared to be nothing in this case, either prior to
injection or in retrospect, which might have raised a warning
flag. Thousands of patients are treated daily in a similar fashion
in phlebology practices worldwide. To our knowledge, there
have been no other published reports of cerebrovascular se-
quelae in the entire history of foam sclerotherapy.1,2 Therefore,
criticism which the article may raise concerning foam sclerother-
apy, a method that has shown powerful advantages of efficiency,
economy, and utility, should be balanced by a careful review of
its positive and negative aspects that have been highlighted in a
series of publications in the last few years.3-10
Because most authors suggest limiting the volume of foam
injected during sclerotherapy, we report here that Morrison et al
prospectively studied 49 consecutive patients undergoing du-
plex-guided foam sclerotherapy. This was reported at the Inter-
national Union of Phlebology American Chapter meeting in
2003 in San Diego. They used 1% polidocanol obtained from a
licensed compounding pharmacy and created foam by the Tes-
sari method in a 4:1 air-to-liquid ratio.11 To achieve mathemat-
ical comparability, the patients were divided into three groups
by the volume of foam injected: low volume, 6 to 21 mL;
medium volume, 22 to 30 mL; and high volume, 31 to 46 mL.
Vital signs and pO2 were monitored during and for 60 minutes
after the procedures.
All patients were followed by telephone interview at 2, 6,
and 24 hours after injection, and any adverse events were
recorded. No significant changes in vital signs or pO2 were seen.
Adverse events included dry cough (14%), chest discomfort
(14%), nausea (4%), dizziness (10%), and visual disturbances
(4%). Of these, only dry cough was statistically related to
increased volumes of foam. All symptoms cleared within 24
hours. Having subsequently replaced room air with carbon
dioxide in the production of foam, adverse events are now only
rarely seen.
Because of concern raised by the Food and Drug Adminis-
tration in the United States regarding embolization after foam
sclerotherapy, Morrison et al subsequently studied 21 patients
with symptoms of visual disturbances or migraine-like headache
after foam sclerotherapy with simultaneous transthoracic echo-
cardiography and foam sclerotherapy. All patients had duplex-
guided injections of 1 to 3 mL of 1% foamed polidocanol into
peripheral leg veins. Foam particles could be identified in the
right heart in all patients within 10 to 30 seconds.
Only cough or Valsalva maneuver in seven of the 21 pa-
tients uncovered a PFO. The incidence of PFO is acknowledged
to be 20% to 30%.12 These seven patients with PFO were studied
with transcranial Doppler during foam sclerotherapy. A few
high-intensity transient signals were identified in the middle cere-
bral artery in 4 of the 7 patients.
Since the vast majority of patients with PFO have much
smaller defects than the 18-mm defect noted in the subject
report, we believe it is totally impractical to screen all patients
for PFO before foam sclerotherapy.
On transthoracic echocardiographic examination of pa-
tients undergoing endovenous laser and radiofrequency abla-
tion of the saphenous vein, many bubbles within the right heart
have been detected during laser ablation and a few bubbles
during radiofrequency ablation. Apparently, right heart bubbles
are not exclusively limited to foam sclerotherapy (Morrison,
unpublished data).
A few remarks concerning the article:
1. There is a lack of detail on foam formation, which directly
influences the size of the bubbles.
2. Related peri-injection procedures such as elevation of the limb
and prolonged immobility are not detailed.
3. The authors correctly point out, but do not emphasize, that the
amount of foam used was excessive compared with published
reports.
In view of the prolonged reversible ischemic neurological
deficit reported by our Irish colleagues, it should be remembered
that the biologic test of thousands of foam treatments daily for
more than 15 years have proven the safety of foam sclerotherapy.
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Regarding “Stroke after varicose vein foam
injection sclerotherapy”
We read with great interest Forlee et al’s report of a patient
who experienced an ischemic stroke moments after undergoing
foam injection sclerotherapy for treatment of varicose veins.1 The
patient was later determined to have a patent foramen ovale. We
commend the authors for having the presence of mind to perform
a carotid duplex scan immediately to reveal what no doubt were
intracarotid bubbles resulting from the foam injection. We note
that the patient received a total of 20 mL of polidocanol foam
prepared by the double syringe method using room air.
We previously demonstrated, using an in vivo model of arte-
riolar embolization after polidocanol microfoam sclerosant admin-
istration, that two prominent—and potentially controllable—
features of foammanufacture contribute to the number and size of
bubbles present as well as the resultant duration of blood flow
obstruction that is caused by the intravascular gas load.2 We found
that foam made with room air, rather than a gas admixture com-
prised of carbon dioxide and oxygen, was directly associated with
increased bubble number and size and caused the longest obstruc-
tion of blood flow. We attribute this to the difference in nitrogen
gas content, as nitrogen is far less soluble and diffusible in tissues
than are metabolic gases. We also found that bubbles made by the
double syringe technique were larger than those created using
mechanisms specifically engineered to dispense microfoams having
a highly controlled bubble size distribution.
We are relieved that the patient recovered significantly, but we
are not surprised by this report of a patient with a patent foramen
ovale experiencing a stroke after foam injection sclerotherapy.
Although we do not think that more careful attention to patient
cardiac anatomy through echocardiographic screening is an effec-
tive means of improving patient safety for this treatment, we do
believe that our previous findings regarding gas content and foam
formation and this case report illustrate the need to change clinical
practice regarding what is injected, and not into whom, to assure
procedural safety.
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Reply
We would like to thank Dr Morrison and Dr Eckmann and
their colleagues for the interest they have shown and the important
points they raise in response to our recent case report.1
The great saphenous vein was cannulated first in order to
minimize the delay between foam production and injection. Foam
was produced using the Tessari method, with a 4:1 air-to-liquid
ratio. Half the volume of foam was injected with the leg on the
level, while compressing the saphenofemoral junction. The leg was
then elevated and the rest of the foam was injected and massaged
into the targeted veins using ultrasound guidance. Compression
stockings were applied with the leg elevated.
With regard to the volume of foam used, we note that in Dr
Morrison’s study using different volumes of foam, our patient
would have been classified in the “low volume” group. Juan
Cabrera, the creator of the patented polidocanol foam, writes that
volumes of 20 mL to 100 mL of foam can be safely used.2 There is,
however, a lack of consensus regarding the optimal volume, and
the European Consensus statement recommends limiting volumes
to 8 mL per treatment using the Tessari method.3
Given the high prevalence of a patent foramen ovale in the
general population, it is surprising that more events have not been
reported. This would imply that most are small and hemodynam-
ically insignificant. We agree that screening before foam injection
would be impractical and probably unnecessary.
Carbon dioxide is absorbed faster than air in the body and has
been shown to produce a foam that degrades quicker.4 The tran-
sient visual symptoms reported in the literature5 are possibly due to
small amounts of air embolism. An argument could thus be made
for carbon dioxide to be used as the carrier gas.
We agree with Drs Eckmann and Kobayashi that the quality of
foam produced is very important, not only with regard to safety but
also efficacy of the procedure. For maximum stability, the size of
the bubbles in the microfoam should ideally be 100m, spheri-
cal, and of uniform size.6 With lack of uniformity in the size of the
bubbles, La Place’s Law (t p/r) dictates that the smaller bubbles
will empty into the bigger bubbles, resulting in larger bubbles with
an increased potential for the air-block effect. Although the Tessari
and other methods have been shown to be effective in producing a
foam that meets these criteria, it is difficult to accurately regulate or
measure bubble size and quality of foam in the clinical setting. This
may be a strong argument for the use of the standardized, com-
mercially produced microfoam preparation when treating varicose
veins.
Foam sclerotherapy has been shown to be safe and efficacious.
Our report describes a rare, but potentially life threatening com-
plication of this treatment.
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